World Health Organization Sounds Concern Over Critical Shortage of Obesity Jabs

Under 10% of individuals that would benefit from obesity jabs like Wegovy have access to them, states the WHO as it publishes its initial advice on the medications.

Considering in excess of 1,000,000,000 people worldwide now obese, it is advocating for increased and just availability to GLP-1 medication.

According to forecasts, more than two billion could be obese by 2030 unless action is taken.

"The new guidelines acknowledges that obesity is a lifelong illness that can be treated with holistic and ongoing care," remarked its chief Tedros Adhanom Ghebreyesus.

Substantial prices, limited production capacity, and supply-chain constraints are key hurdles to widespread availability to the treatments that can aid individuals in losing considerable weight, explains the body.

Skinny Jab Shortage

Despite the present most favorable outlook, the production of these medications could only cover about 100 million people – less than 10% of those who need them, per the WHO.

The advice urges nations and manufacturers to expand availability, through approaches such as patent sharing.

Exclusive production rights on a key compound – the main component of the drug Wegovy – is due to expire in several nations in 2026.

How Obesity Jabs Operate

These medications mimick a body's own hormone to reduce digestion speed, curb appetite and enhance the sense of being full so people eat less.

Individuals typically see weight reduction in the initial weeks of commencing the once-weekly jabs.

Research points to users may put most of the weight back on within a year of stopping the medication, because their normal food cravings resume.

Being above a healthy weight increases your likelihood for experiencing medical conditions, such as type 2 diabetes, cardiovascular issues, brain attack, and some cancers.

Excess weight affects individuals in countries worldwide and was linked to 3.7 million fatalities worldwide in 2024, per the health agency.